RadNet. to Acquire iCAD. to Accelerate AI-Powered Early Detection, Diagnosis of Breast Cancer

 

• The acquisition will unite complementary leading AI-powered cancer detection and workflow solutions focused on improving the accuracy and early detection of breast cancer
• The transaction is expected to add to RadNet’s wholly owned subsidiary, DeepHealth, an installed base of over 1,500 healthcare provider locations across over 50 countries
• With iCAD’s seasoned commercial and engineering team anticipated to join DeepHealth, the combination is expected to accelerate RadNet’s growth and leadership in cancer screening and artificial intelligence
• Following the completion of the acquisition, iCAD will be integrated into RadNet’s DeepHealth portfolio of solutions
• RadNet will host a conference call and webcast at 10:30 a.m. ET tomorrow, April 16, 2025, to discuss the transaction

Conference Call Details:

Date: April 16, 2025
Time: 10:30 a.m. ET / 7:30 a.m. PT
Dial In-Number: 844-826-3035
International Dial-In Number: 412-317-5195

There will also be simultaneous and archived webcasts available at https://viavid.webcasts.com/starthere.jsp?ei=1716330&tp_key=176fbd27c7 or http://www.radnet.com under the “About RadNet” menu section and “News & Press Releases” sub-menu of the website. An archived replay of the call will also be available and can be accessed by dialing 844-512-2921 from the U.S., or 412-317-6671 for international callers, and using the passcode 10199100.

https://www.globenewswire.com/news-release/2025/04/15/3062106/0/en/RadNet-Inc-to-Acquire-iCAD-Inc-to-Accelerate-AI-Powered-Early-Detection-and-Diagnosis-of-Breast-Cancer.html